Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Amortization of Deferred Charges (2019 - 2024)

Historic Amortization of Deferred Charges for ImmunityBio (IBRX) over the last 4 years, with Q4 2024 value amounting to $5.0 million.

  • ImmunityBio's Amortization of Deferred Charges fell 2965.72% to $5.0 million in Q4 2024 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 7972.71%. This contributed to the annual value of $22.6 million for FY2024, which is 4672.37% down from last year.
  • Latest data reveals that ImmunityBio reported Amortization of Deferred Charges of $5.0 million as of Q4 2024, which was down 2965.72% from $6.2 million recorded in Q3 2024.
  • ImmunityBio's 5-year Amortization of Deferred Charges high stood at $12.3 million for Q2 2023, and its period low was $370000.0 during Q1 2022.
  • Its 3-year average for Amortization of Deferred Charges is $6.8 million, with a median of $6.0 million in 2024.
  • In the last 5 years, ImmunityBio's Amortization of Deferred Charges soared by 301783.78% in 2023 and then crashed by 5253.91% in 2024.
  • ImmunityBio's Amortization of Deferred Charges (Quarter) stood at $7.8 million in 2022, then decreased by 8.2% to $7.1 million in 2023, then fell by 29.66% to $5.0 million in 2024.
  • Its last three reported values are $5.0 million in Q4 2024, $6.2 million for Q3 2024, and $5.8 million during Q2 2024.